Alcohol-Related Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease: Molecular Pathogenesis and Therapeutic Interventions

Abstract

Alcohol-related liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD) are among the most prevalent chronic liver conditions globally, placing a substantial burden on global healthcare systems. Although significant progress has been made in their study, the pathogenic mechanisms remain incompletely defined, and effective treatments are still limited. This review aims to provide a comprehensive analysis of the shared and divergent molecular pathogenic mechanisms underlying these two diseases and to systematically summarize the latest therapeutic intervention strategies. Although ALD and MASLD have distinct etiologies, they share multiple pathophysiological pathways, such as dysregulated lipid metabolism, programmed cell death, cellular senescence, gut dysbiosis, and immune activation. We focus on key molecular events within these shared pathways, such as impaired fatty acid oxidation, increased lipogenesis, activation of pyroptotic and necroptotic signaling pathways, engagement of the p53–p21 senescence axis, and gut microbiota-driven immune signaling pathways via microbial metabolites and microbe-associated molecular patterns. Building upon these mechanistic insights, the review further outlines therapeutic strategies targeting lipid metabolism, cell death, cellular senescence, microbiota modulation, and immunomodulation, while also discussing the specific challenges and opportunities. Ultimately, this review proposes a mechanistic framework to guide the development of precision therapies for ALD and MASLD.

Keywords

alcoholic liver disease / immune regulation / intestinal microbiota / metabolism-related fatty liver disease / molecular mechanisms / treatment strategies

References

[1] H. Devarbhavi, S. K. Asrani, J. P. Arab, Y. A. Nartey, E. L. S. Pose, and P. S. Kamath, “Global Burden of Liver Disease: 2023 Update,” Journal of Hepatology 79, no. 2 (2023): 516–537.

[2] M. Thursz, P. S. Kamath, P. Mathurin, G. Szabo, and V. H. Shah, “Alcohol-related Liver Disease: Areas of Consensus, Unmet Needs and Opportunities for Further Study,” Journal of Hepatology 70, no. 3 (2019): 521–530.

[3] J. Manthey, K. D. Shield, M. Rylett, O. S. M. Hasan, C. Probst, and J. Rehm, “Global Alcohol Exposure Between 1990 and 2017 and Forecasts Until 2030: A Modelling Study,” The Lancet 393, no. 10190 (2019): 2493–2502.

[4] T. Vos, S. S. Lim, C. Abbafati, et al., “Global Burden of 369 Diseases and Injuries in 204 Countries and territories, 1990–2019: A Systematic Analysis for the Global Burden of Disease Study 2019,” Lancet 396, no. 10258 (2020): 1204–1222.

[5] Z. Yang, Z. Liu, W. Liu, and X. C. Dong, “Steatotic Liver Disease and Cancer: From Pathogenesis to Therapeutic Targets,” eGastroenterology 3, no. 3 (2025): e100218.

[6] M. Eslam, A. J. Sanyal, J. George, et al., “MAFLD: A Consensus-driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease,” Gastroenterology 158, no. 7 (2020): 1999–2014. e1.

[7] Z. M. Younossi, P. Golabi, J. M. Paik, A. Henry, C. Van Dongen, and L. Henry, “The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review,” Hepatology 77, no. 4 (2023): 1335–1347.

[8] R. J. Wong, M. Aguilar, R. Cheung, et al., “Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States,” Gastroenterology 148, no. 3 (2015): 547–555.

[9] M. E. Rinella, J. V. Lazarus, V. Ratziu, et al., “A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature,” Annals of Hepatology 29, no. 1 (2024): 101133.

[10] X. Q. Wu, X. D. Fan, T. Miyata, et al., “Recent Advances in Understanding of Pathogenesis of Alcohol-associated Liver Disease,” Annual Review of Pathology: Mechanisms of Disease 18, no. 1 (2023): 411–438.

[11] R. Wang, R. Q. Tang, B. Li, X. Ma, B. Schnabl, and H. Tilg, “Gut Microbiome, Liver Immunology, and Liver Diseases,” Cellular & Molecular Immunology 18, no. 1 (2021): 4–17.

[12] Y. X. Li, P. P. Yang, J. L. Ye, Q. Y. Xu, J. Q. Wu, and Y. D. Wang, “Updated Mechanisms of MASLD Pathogenesis,” Lipids in Health and Disease 23, no. 1 (2024): 117.

[13] R. Benedé-Ubieto, F. J. Cubero, and Y. A. Nevzorova, “Breaking the Barriers: The Role of Gut Homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD),” Gut Microbes 16, no. 1 (2024): 2331460.

[14] P. G. Thomes, K. Rasineni, L. Yang, et al., “Ethanol Withdrawal Mitigates Fatty Liver by Normalizing Lipid Catabolism,” American Journal of Physiology-Gastrointestinal and Liver Physiology 316, no. 4 (2019): G509–G518.

[15] J. Krammer, M. Digel, F. Ehehalt, W. Stremmel, J. Füllekrug, and R. Ehehalt, “Overexpression of CD36 and Acyl-CoA Synthetases FATP2, FATP4 and ACSL1 Increases Fatty Acid Uptake in human Hepatoma Cells,” International Journal of Medical Sciences 8, no. 7 (2011): 599–614.

[16] M. Kan, R. N. Wang, L. Chen, et al., “Insulin-Like Growth Factor-binding Protein 7 Exacerbates Inflammatory Response and Lipid Metabolism Imbalance in Alcohol-associated Liver Disease,” Free Radical Biology & Medicine 224 (2024): 809–821.

[17] Y. Liu, M. Zhang, C. Zhu, et al., “FATP5 deficiency Alleviates MASH via Remodeling Hepatic Lipid Composition to Suppress Ferroptosis,” Free Radical Biology and Medicine 240 (2025): 170–182.

[18] A. Falcon, H. Doege, A. Fluitt, et al., “FATP2 is a Hepatic Fatty Acid Transporter and Peroxisomal Very Long-chain Acyl-CoA Synthetase,” American Journal of Physiology. Endocrinology and Metabolism 299, no. 3 (2010): E384–393.

[19] Y.-Y. Qiu, J. Zhang, F.-Y. Zeng, and Y. Z. Zhu, “Roles of the Peroxisome Proliferator-activated Receptors (PPARs) in the Pathogenesis of Nonalcoholic Fatty Liver Disease (NAFLD),” Pharmacological Research 192 (2023): 106786.

[20] M. Bedoucha, E. Atzpodien, and U. A. Boelsterli, “Diabetic KKAy Mice Exhibit Increased Hepatic PPARgamma1 Gene Expression and Develop Hepatic Steatosis Upon Chronic Treatment With Antidiabetic Thiazolidinediones,” Journal of Hepatology 35, no. 1 (2001): 17–23.

[21] C. Zhang, X. Luo, J. Chen, et al., “Osteoprotegerin Promotes Liver Steatosis by Targeting the ERK-PPAR-γ-CD36 Pathway,” Diabetes 68, no. 10 (2019): 1902–1914.

[22] X. Cai, Q. Zhang, J. Wang, et al., “Novel Dual PPAR δ/γ Partial Agonist Induces Hepatic Lipid Accumulation Through Direct Binding and Inhibition of AKT1 Phosphorylation, Mediating CD36 Upregulation,” Chemical Research in Toxicology 37, no. 9 (2024): 1574–1587.

[23] F. Chen, T. Hao, Q. Chen, et al., “FABP1 induces Lipogenesis by Regulating the Processing of SREBP1 in Hepatocytes of Large Yellow Croaker (Larimichthys crocea),” Faseb Journal 38, no. 18 (2024): e70036.

[24] A. Baumann, K. Burger, A. Brandt, et al., “GW9662, a Peroxisome Proliferator-activated Receptor Gamma Antagonist, Attenuates the Development of Non-alcoholic Fatty Liver Disease,” Metabolism 133 (2022): 155233.

[25] X. Wang, J. Hong, R. Liang, et al., “Obacunone Ameliorates High-fat Diet-induced MAFLD by Regulating the PPARγ-FABP1/CD36 Axis and the Gut-liver Crosstalk,” Phytomedicine 147 (2025): 157180.

[26] M. Hu, F. M. Wang, X. Li, et al., “Regulation of Hepatic Lipin-1 by Ethanol: Role of AMP-activated Protein Kinase/Sterol Regulatory Element-binding Protein 1 Signaling in Mice,” Hepatology 55, no. 2 (2012): 437–446.

[27] Y. Zhang, Y. Li, Y. Liu, et al., “Alcoholic Setdb1 Suppression Promotes Hepatosteatosis in Mice by Strengthening Plin2,” Metabolism 146 (2023): 155656.

[28] Y. Tang, H. Zhou, X. Pan, Z. Zhong, H. Liu, and Y. Guo, “Arrestin Domain Containing 3 Promotes Alcohol-induced Liver Steatosis by Reducing Stearoyl-CoA Desaturase-1 Ubiquitinated Degradation,” Metabolism 167 (2025): 156175.

[29] Y. Zhang, X. Miao, F. Liu, et al., “ASPP2 deficiency Attenuates Lipid Accumulation Through the PPARγ Pathway in Alcoholic Liver Injury,” Cell Biology and Toxicology 40, no. 1 (2024): 102.

[30] Q. Yan, Q. Fang, Z. A. Chen, L. J. Chen, and J. Du, “RNF2 modulates Lipid Metabolism and Inflammation in Alcohol-associated Liver Disease by Interacting With USP7,” International Journal of Biological Sciences 21, no. 7 (2025): 3306–3323.

[31] X. P. Zhu, H. Bian, L. Wang, et al., “Berberine Attenuates Nonalcoholic Hepatic Steatosis Through the AMPK-SREBP-1c-SCD1 Pathway,” Free Radical Biology & Medicine 141 (2019): 192–204.

[32] R. Li, Y. Li, X. Yang, Y. Hu, H. Yu, and Y. Li, “Reducing VEGFB Accelerates NAFLD and Insulin Resistance in Mice via Inhibiting AMPK Signaling Pathway,” Journal of Translational Medicine 20, no. 1 (2022): 341.

[33] F. Benhamed, P.-D. Denechaud, M. Lemoine, et al., “The Lipogenic Transcription Factor ChREBP Dissociates Hepatic Steatosis From Insulin Resistance in Mice and Humans,” Journal of Clinical Investigation 122, no. 6 (2012): 2176–2194.

[34] K. Iizuka, K. Takao, and D. Yabe, “ChREBP-Mediated Regulation of Lipid Metabolism: Involvement of the Gut Microbiota, Liver, and Adipose Tissue,” Frontiers in Endocrinology (Lausanne) 11 (2020): 587189.

[35] K. Iizuka, R. K. Bruick, G. Liang, J. D. Horton, and K. Uyeda, “Deficiency of Carbohydrate Response Element-binding Protein (ChREBP) Reduces Lipogenesis as Well as Glycolysis,” PNAS 101, no. 19 (2004): 7281–7286.

[36] A. Tailleux, K. Wouters, and B. Staels, “Roles of PPARs in NAFLD: Potential Therapeutic Targets,” Biochimica Et Biophysica Acta 1821, no. 5 (2012): 809–818.

[37] M. Szántó, R. Gupte, W. L. Kraus, P. Pacher, and P. Bai, “PARPs in Lipid Metabolism and Related Diseases,” Progress in Lipid Research 84 (2021): 101117.

[38] H. X. Xu, J. Y. Shi, W. J. Yu, et al., “TBC1D15 protects Alcohol-induced Liver Injury in Female Mice Through PLIN5-mediated Mitochondrial and Lipid Droplet Contacting,” Metabolism 169 (2025): 156290.

[39] J. Feng, L. MengHuan, Y. TingTing, Y. XueJie, and G. HaiNing, “Research Progress on AMPK in the Pathogenesis and Treatment of MASLD,” Frontiers in Immunology 16 (2025): 1558041.

[40] Y. Gao, W. Zhang, L.-Q. Zeng, et al., “Exercise and Dietary Intervention Ameliorate High-fat Diet-induced NAFLD and Liver Aging by Inducing Lipophagy,” Redox Biology 36 (2020): 101635.

[41] L.-C. Lew, Y.-Y. Hor, M.-H. Jaafar, et al., “Lactobacillus Strains Alleviated Hyperlipidemia and Liver Steatosis in Aging Rats via Activation of AMPK,” International Journal of Molecular Sciences 21, no. 16 (2020): 5872.

[42] Y.-H. Lee, M. R. Yun, H. M. Kim, et al., “Exogenous Administration of DLK1 Ameliorates Hepatic Steatosis and Regulates Gluconeogenesis via Activation of AMPK,” International Journal of Obesity (London) 40, no. 2 (2016): 356–365.

[43] X. T. Zhao, C. Wang, S. Dai, et al., “Quercetin Protects Ethanol-induced Hepatocyte Pyroptosis via Scavenging Mitochondrial ROS and Promoting PGC-1 α -regulated Mitochondrial Homeostasis in L02 Cells,” Oxidative Medicine and Cellular Longevity 2022, no. 1 (2022): 4591134.

[44] M. Pawlak, P. Lefebvre, and B. Staels, “Molecular Mechanism of PPARα Action and Its Impact on Lipid Metabolism, Inflammation and Fibrosis in Non-alcoholic Fatty Liver Disease,” Journal of Hepatology 62, no. 3 (2015): 720–733.

[45] C. Z. Larter, M. M. Yeh, D. M. Van Rooyen, J. Brooling, K. Ghatora, and G. C. Farrell, “Peroxisome Proliferator-activated Receptor-α Agonist, Wy 14,643, Improves Metabolic Indices, Steatosis and Ballooning in Diabetic Mice With Non-alcoholic Steatohepatitis,” Journal of Gastroenterology and Hepatology 27, no. 2 (2012): 341–350.

[46] M. Weber, P. Mera, J. Casas, et al., “Liver CPT1A Gene Therapy Reduces Diet-induced Hepatic Steatosis in Mice and Highlights Potential Lipid Biomarkers for human NAFLD,” Faseb Journal 34, no. 9 (2020): 11816–11837.

[47] Q. C. Ding, F. W. Cao, H. Zhuge, et al., “Hepatic NMNAT1 Is Required to Defend Against Alcohol-associated Fatty Liver Disease,” Science Advances 11, no. 26 (2025): eadt6195.

[48] T. Ota, C. Gayet, and H. N. Ginsberg, “Inhibition of Apolipoprotein B100 Secretion by Lipid-induced Hepatic Endoplasmic Reticulum Stress in Rodents,” Journal of Clinical Investigation 118, no. 1 (2008): 316–332.

[49] M. Charlton, R. Sreekumar, D. Rasmussen, K. Lindor, and K. S. Nair, “Apolipoprotein Synthesis in Nonalcoholic Steatohepatitis,” Hepatology 35, no. 4 (2002): 898–904.

[50] N. Shindo, T. Fujisawa, K. Sugimoto, et al., “Involvement of Microsomal Triglyceride Transfer Protein in Nonalcoholic Steatohepatitis in Novel Spontaneous Mouse Model,” Journal of Hepatology 52, no. 6 (2010): 903–912.

[51] N. Berriot-Varoqueaux, L. P. Aggerbeck, M.-E. Samson-Bouma, and J. R. Wetterau, “The Role of the Microsomal Triglygeride Transfer Protein in Abetalipoproteinemia,” Annual Review of Nutrition 20, no. 1 (2000): 663–697.

[52] T. Tanoli, P. Yue, D. Yablonskiy, and G. Schonfeld, “Fatty Liver in Familial Hypobetalipoproteinemia: Roles of the APOB Defects, Intra-abdominal Adipose Tissue, and Insulin Sensitivity,” Journal of Lipid Research 45, no. 5 (2004): 941–947.

[53] Y. S. Jung, K. Radhakrishnan, S. Hammad, et al., “ERRγ-inducible FGF23 Promotes Alcoholic Liver Injury Through Enhancing CYP2E1 Mediated Hepatic Oxidative Stress,” Redox Biology 71 (2024): 103107.

[54] E. Khanova, R. Wu, W. Wang, et al., “Pyroptosis by caspase11/4-gasdermin-D Pathway in Alcoholic hepatitis in Mice and Patients,” Hepatology 67, no. 5 (2018): 1737–1753.

[55] M. J. Heo, T. H. Kim, J. S. You, D. Blaya, P. Sancho-Bru, and S. G. Kim, “Alcohol Dysregulates miR-148a in Hepatocytes Through FoxO1, Facilitating Pyroptosis via TXNIP Overexpression,” Gut 68, no. 4 (2019): 708–720.

[56] M. Wang, X. Wen, Z. Feng, et al., “ACSS2 protects Against Alcohol-induced Hepatocyte Ferroptosis Through Regulation of Hepcidin Expression,” Nature Communications 16, no. 1 (2025): 5491.

[57] Y. J. Zhou, N. Z. Pang, W. L. Li, et al., “Inhibition of Ethanol-induced eNAMPT Secretion Attenuates Liver Ferroptosis Through BAT-liver Communication,” Redox Biology 75 (2024): 103274.

[58] Y. J. You, C. X. Liu, T. T. Liu, et al., “FNDC3B protects Steatosis and Ferroptosis via the AMPK Pathway in Alcoholic Fatty Liver Disease,” Free Radical Biology & Medicine 193, no. Pt 2 (2022): 808–819.

[59] T. T. Pan, S. J. Wu, S. H. Wang, X. D. Wang, D. Z. Chen, and Y. P. Chen, “Novel Insights Into Cuproptosis in Alcoholic Liver Disease Using Bioinformatics Analysis and Experimental Validation,” International Immunopharmacology 146 (2025): 113828.

[60] J. F. Li, Y. Wang, Z. Wu, et al., “Identification of Diagnostic Markers and Molecular Clusters of Cuproptosis-related Genes in Alcohol-related Liver Disease Based on Machine Learning and Experimental Validation,” Heliyon 10, no. 18 (2024): e37612.

[61] Z. Cheng, H. Chu, E. Seki, R. Lin, and L. Yang, “Hepatocyte Programmed Cell Death: The Trigger for Inflammation and Fibrosis in Metabolic Dysfunction-associated Steatohepatitis,” Frontiers in Cell and Developmental Biology 12 (2024): 1431921.

[62] H. Xu, S. Wan, Y. An, et al., “Targeting Cell Death in NAFLD: Mechanisms and Targeted Therapies,” Cell Death Discovery 10, no. 1 (2024): 399.

[63] N. Alkhouri, A. Alisi, V. Okwu, et al., “Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children With Nonalcoholic Steatohepatitis,” Digestive Diseases and Sciences 60, no. 8 (2015): 2353–2359.

[64] J. Crespo, A. Cayón, P. Fernández-Gil, et al., “Gene Expression of Tumor Necrosis Factor Alpha and TNF-receptors, p55 and p75, in Nonalcoholic Steatohepatitis Patients,” Hepatology 34, no. 6 (2001): 1158–1163.

[65] M. B. Afonso, R. E. Castro, and C. M. P. Rodrigues, “Processes Exacerbating Apoptosis in Non-alcoholic Steatohepatitis,” Clinical Science (London, England: 1979) 133, no. 22 (2019): 2245–2264.

[66] M. Hatting, G. Zhao, F. Schumacher, et al., “Hepatocyte Caspase-8 Is an Essential Modulator of Steatohepatitis in Rodents,” Hepatology 57, no. 6 (2013): 2189–2201.

[67] L. Shojaie, A. Iorga, and L. Dara, “Cell Death in Liver Diseases: A Review,” International Journal of Molecular Sciences 21, no. 24 (2020): 9682.

[68] P. Hirsova, S. H. Ibrahim, S. F. Bronk, H. Yagita, and G. J. Gores, “Vismodegib Suppresses TRAIL-mediated Liver Injury in a Mouse Model of Nonalcoholic Steatohepatitis,” PLoS ONE 8, no. 7 (2013): e70599.

[69] B. Khambu, S. Yan, N. Huda, G. Liu, and X.-M. Yin, “Autophagy in Non-alcoholic Fatty Liver Disease and Alcoholic Liver Disease,” Liver Research 2, no. 3 (2018): 112–119.

[70] S. Tanaka, H. Hikita, T. Tatsumi, et al., “Rubicon Inhibits Autophagy and Accelerates Hepatocyte Apoptosis and Lipid Accumulation in Nonalcoholic Fatty Liver Disease in Mice,” Hepatology 64, no. 6 (2016): 1994–2014.

[71] C.-S. Cho, H.-W. Park, A. Ho, et al., “Lipotoxicity Induces Hepatic Protein Inclusions Through TANK Binding Kinase 1-mediated p62/Sequestosome 1 Phosphorylation,” Hepatology 68, no. 4 (2018): 1331–1346.

[72] S. Ezquerro, F. Mocha, G. Frühbeck, et al., “Ghrelin Reduces TNF-α-Induced Human Hepatocyte Apoptosis, Autophagy, and Pyroptosis: Role in Obesity-Associated NAFLD,” Journal of Clinical Endocrinology and Metabolism 104, no. 1 (2019): 21–37.

[73] I. Katsaros, M. Sotiropoulou, M. Vailas, et al., “Quercetin's Potential in MASLD: Investigating the Role of Autophagy and Key Molecular Pathways in Liver Steatosis and Inflammation,” Nutrients 16, no. 22 (2024): 3789.

[74] Q. Zhao, Z. Guo, W. Deng, et al., “Calpain 2-mediated Autophagy Defect Increases Susceptibility of Fatty Livers to Ischemia-reperfusion Injury,” Cell Death & Disease 7, no. 4 (2016): e2186.

[75] A. González-Rodríguez, R. Mayoral, N. Agra, et al., “Impaired Autophagic Flux Is Associated With Increased Endoplasmic Reticulum Stress During the Development of NAFLD,” Cell Death & Disease 5, no. 4 (2014): e1179.

[76] S. Gaul, A. Leszczynska, F. Alegre, et al., “Hepatocyte Pyroptosis and Release of Inflammasome Particles Induce Stellate Cell Activation and Liver Fibrosis,” Journal of Hepatology 74, no. 1 (2021): 156–167.

[77] J. I. Beier and J. M. Banales, “Pyroptosis: An Inflammatory Link Between NAFLD and NASH With Potential Therapeutic Implications,” Journal of Hepatology 68, no. 4 (2018): 643–645.

[78] J. Shi, Y. Zhao, K. Wang, et al., “Cleavage of GSDMD by Inflammatory Caspases Determines Pyroptotic Cell Death,” Nature 526, no. 7575 (2015): 660–665.

[79] Y. Bordon, “Cell Death and Immunity: Gasdermins: The Hole Picture Emerges,” Nature Reviews Immunology 16, no. 7 (2016): 401.

[80] P. Broz, P. Pelegrín, and F. Shao, “The Gasdermins, a Protein family Executing Cell Death and Inflammation,” Nature Reviews Immunology 20, no. 3 (2020): 143–157.

[81] R. Zhao, Z. Guo, K. Lu, et al., “Hepatocyte-specific NR5A2 Deficiency Induces Pyroptosis and Exacerbates Non-alcoholic Steatohepatitis by Downregulating ALDH1B1 Expression,” Cell Death & Disease 15, no. 10 (2024): 770.

[82] S. Luo, Z. Lu, L. Wang, Y. Li, Y. Zeng, and H. Lu, “Hepatocyte HIF-2α Aggravates NAFLD by Inducing Ferroptosis Through Increasing Extracellular Iron,” American Journal of Physiology. Endocrinology and Metabolism 328, no. 1 (2025): E92–E104.

[83] Y. Li, P. Qi, S.-Y. Song, et al., “Elucidating Cuproptosis in Metabolic Dysfunction-associated Steatotic Liver Disease,” Biomedicine & Pharmacotherapy 174 (2024): 116585.

[84] G. Ouyang, Z. Wu, Z. Liu, et al., “Identification and Validation of Potential Diagnostic Signature and Immune Cell Infiltration for NAFLD Based on Cuproptosis-related Genes by Bioinformatics Analysis and Machine Learning,” Frontiers in Immunology 14 (2023): 1251750.

[85] P. Tsvetkov, S. Coy, B. Petrova, et al., “Copper Induces Cell Death by Targeting Lipoylated TCA Cycle Proteins,” Science 375, no. 6586 (2022): 1254–1261.

[86] F. Bardag-Gorce, J. Oliva, A. Lin, J. Li, B. A. French, and S. W. French, “Proteasome Inhibitor up Regulates Liver Antioxidative Enzymes in Rat Model of Alcoholic Liver Disease,” Experimental and Molecular Pathology 90, no. 1 (2011): 123–130.

[87] C. F. Lu, T. Ge, Y. Y. Shao, et al., “ZNF281 drives Hepatocyte Senescence in Alcoholic Liver Disease by Reducing HK2 -stabilized PINK1 /Parkin-mediated Mitophagy,” Cell Proliferation 56, no. 3 (2023): e13378.

[88] T. T. Schug and X. L. Li, “Sirtuin 1 in Lipid Metabolism and Obesity,” Annals of Medicine 43, no. 3 (2011): 198–211.

[89] M. Li, Y. He, Z. Zhou, et al., “MicroRNA-223 Ameliorates Alcoholic Liver Injury by Inhibiting the IL-6–p47^phox –oxidative Stress Pathway in Neutrophils,” Gut 66, no. 4 (2017): 705–715.

[90] M. You, A. Jogasuria, C. Taylor, and J. Wu, “Sirtuin 1 Signaling and Alcoholic Fatty Liver Disease,” Hepatobiliary Surg Nutr 4, no. 2 (2015): 88–100.

[91] W. Huang, L. J. Hickson, A. Eirin, J. L. Kirkland, and L. O. Lerman, “Cellular Senescence: The Good, the Bad and the Unknown,” Nature Reviews Nephrology 18, no. 10 (2022): 611–627.

[92] L. Petagine, M. G. Zariwala, and V. B. Patel, “Alcoholic Liver Disease: Current Insights Into Cellular Mechanisms,” World Journal of Biological Chemistry 12, no. 5 (2021): 87–103.

[93] A. K. Palmer, T. Tchkonia, and J. L. Kirkland, “Targeting Cellular Senescence in Metabolic Disease,” Molecular Metabolism 66 (2022): 101601.

[94] A. S. Meijnikman, H. Herrema, T. P. M. Scheithauer, J. Kroon, M. Nieuwdorp, and A. K. Groen, “Evaluating Causality of Cellular Senescence in Non-alcoholic Fatty Liver Disease,” JHEP Reports 3, no. 4 (2021): 100301.

[95] I. I. Moustakas, A. Katsarou, A.-I. Legaki, et al., “Hepatic Senescence Accompanies the Development of NAFLD in Non-Aged Mice Independently of Obesity,” International Journal of Molecular Sciences 22, no. 7 (2021): 3446.

[96] J. Zhang, Y. P. Li, B. Y. Wang, Y. Luo, J. P. Shi, and B. Y. Zhao, “The p66shc-mediated Regulation of Hepatocyte Senescence Influences Hepatic Steatosis in Nonalcoholic Fatty Liver Disease,” Medical Science Monitor 26 (2020): e921887.

[97] M. Ogrodnik, S. Miwa, T. Tchkonia, et al., “Cellular Senescence Drives Age-dependent Hepatic Steatosis,” Nature Communications 8 (2017): 15691.

[98] N. J. Hunt, S. W. S. Kang, G. P. Lockwood, D. G. Le Couteur, and V. C. Cogger, “Hallmarks of Aging in the Liver,” Computational and Structural Biotechnology Journal 17 (2019): 1151–1161.

[99] M. J. Caldez, M. Bjorklund, and P. Kaldis, “Cell Cycle Regulation in NAFLD: When Imbalanced Metabolism Limits Cell Division,” Hepatology International 14, no. 4 (2020): 463–474.

[100] J. S. Bajaj, “Alcohol, Liver Disease and the Gut Microbiota,” Nature reviews Gastroenterology & hepatology 16, no. 4 (2019): 235–246.

[101] J. Chen and L. Vitetta, “Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications,” International Journal of Molecular Sciences 21, no. 15 (2020): 5214.

[102] J. S. Bajaj and P. B. Hylemon, “Gut–liver Axis Alterations in Alcoholic Liver Disease: Are Bile Acids the Answer?,” Hepatology 67, no. 6 (2018): 2074–2075.

[103] H. Wu, J. Chen, S. Guo, et al., “Advances in the Acting Mechanism and Treatment of Gut Microbiota in Metabolic Dysfunction-associated Steatotic Liver Disease,” Gut Microbes 17, no. 1 (2025): 2500099.

[104] V. B. Dubinkina, A. V. Tyakht, V. Y. Odintsova, et al., “Links of Gut Microbiota Composition With Alcohol Dependence Syndrome and Alcoholic Liver Disease,” Microbiome 5, no. 1 (2017): 141.

[105] Y. Fan, Z. Ya-E, W. Ji-Dong, et al., “Comparison of Microbial Diversity and Composition in Jejunum and Colon of the Alcohol-dependent Rats,” Journal of Microbiology and Biotechnology 28, no. 11 (2018): 1883–1895.

[106] J. S. Bajaj, D. M. Heuman, P. B. Hylemon, et al., “Altered Profile of human Gut Microbiome Is Associated With Cirrhosis and Its Complications,” Journal of Hepatology 60, no. 5 (2014): 940–947.

[107] A. W. Yan, D. E. Fouts, J. Brandl, et al., “Enteric Dysbiosis Associated With a Mouse Model of Alcoholic Liver Disease,” Hepatology 53, no. 1 (2011): 96–105.

[108] D. Ciocan, C. S. Voican, L. Wrzosek, et al., “Bile Acid Homeostasis and Intestinal Dysbiosis in Alcoholic hepatitis,” Alimentary Pharmacology & Therapeutics 48, no. 9 (2018): 961–974.

[109] E. Smirnova, P. Puri, M. D. Muthiah, et al., “Fecal Microbiome Distinguishes Alcohol Consumption From Alcoholic hepatitis but Does Not Discriminate Disease Severity,” Hepatology 72, no. 1 (2020): 271–286.

[110] R. Ganesan, H. Gupta, J.-J. Jeong, et al., “Characteristics of Microbiome-derived Metabolomics According to the Progression of Alcoholic Liver Disease,” Hepatology International 18, no. 2 (2024): 486–499.

[111] N. Verma, S. Singh, M. Singh, et al., “Global Epidemiological Burden of Fungal Infections in Cirrhosis Patients: A Systematic Review With Meta-analysis,” Mycoses 65, no. 3 (2022): 266–284.

[112] P. Hartmann, S. Lang, S. Zeng, et al., “Dynamic Changes of the Fungal Microbiome in Alcohol Use Disorder,” Frontiers in Physiology 12 (2021): 699253.

[113] J. S. Bajaj, E. J. Liu, R. Kheradman, et al., “Fungal Dysbiosis in Cirrhosis,” Gut 67, no. 6 (2018): 1146–1154.

[114] H. K. Chu, Y. Duan, S. Lang, et al., “The candida albicans Exotoxin Candidalysin Promotes Alcohol-associated Liver Disease,” Journal of Hepatology 72, no. 3 (2020): 391–400.

[115] A.-M. Yang, T. Inamine, K. Hochrath, et al., “Intestinal Fungi Contribute to Development of Alcoholic Liver Disease,” The Journal of Clinical Investigation 127, no. 7 (2017): 2829–2841.

[116] S. L. Zeng, P. Hartmann, M. Park, et al., “Malassezia restricta Promotes Alcohol-induced Liver Injury,” Hepatology Communications 7, no. 2 (2023): e0029–e0029.

[117] H. Izu, M. Shobayashi, Y. Manabe, K. Goto, and H. Iefuji, “Sake Yeast Suppresses Acute Alcohol-induced Liver Injury in Mice,” Bioscience, Biotechnology, and Biochemistry 70, no. 10 (2006): 2488–2493.

[118] S. Lang, Y. Duan, J. Liu, et al., “Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic hepatitis,” Hepatology (Baltimore, Md) 71, no. 2 (2020): 522–538.

[119] L. Jiang, S. Lang, Y. Duan, et al., “Intestinal Virome in Patients With Alcoholic hepatitis,” Hepatology (Baltimore, Md) 72, no. 6 (2020): 2182–2196.

[120] N. Cabré, P. Hartmann, C. Llorente, et al., “IgY Antibodies Against Cytolysin Reduce Ethanol-induced Liver Disease in Mice,” Hepatology 78, no. 1 (2023): 295–306.

[121] Y. Duan, C. Llorente, S. Lang, et al., “Bacteriophage Targeting of Gut Bacterium Attenuates Alcoholic Liver Disease,” Nature 575, no. 7783 (2019): 505–511.

[122] Y. Q. Yang, Y. Duan, S. Lang, et al., “Targeted Inhibition of Pathobiont Virulence Factor Mitigates Alcohol-associated Liver Disease,” Cell Host & Microbe 33, no. 6 (2025): 957–972. e6.

[123] G. Viebahn, P. Hartmann, S. Lang, et al., “Fungal Signature Differentiates Alcohol-associated Liver Disease From Nonalcoholic Fatty Liver Disease,” Gut Microbes 16, no. 1 (2024): 2307586.

[124] F. Shen, R.-D. Zheng, X.-Q. Sun, W.-J. Ding, X.-Y. Wang, and J.-G. Fan, “Gut Microbiota Dysbiosis in Patients With Non-alcoholic Fatty Liver Disease,” Hepatobiliary & Pancreatic Diseases International 16, no. 4 (2017): 375–381.

[125] S. Astbury, E. Atallah, A. Vijay, G. P. Aithal, J. I. Grove, and A. M. Valdes, “Lower Gut Microbiome Diversity and Higher Abundance of Proinflammatory Genus Collinsella Are Associated With Biopsy-proven Nonalcoholic Steatohepatitis,” Gut Microbes 11, no. 3 (2020): 569–580.

[126] S. Michail, M. Lin, M. R. Frey, et al., “Altered Gut Microbial Energy and Metabolism in Children With Non-alcoholic Fatty Liver Disease,” Fems Microbiology Ecology 91, no. 2 (2015): 1–9.

[127] A. Sobhonslidsuk, S. Chanprasertyothin, T. Pongrujikorn, et al., “The Association of Gut Microbiota With Nonalcoholic Steatohepatitis in thais,” BioMed Research International 2018 (2018): 1–8.

[128] J. Behary, N. Amorim, X.-T. Jiang, et al., “Gut Microbiota Impact on the Peripheral Immune Response in Non-alcoholic Fatty Liver Disease Related Hepatocellular Carcinoma,” Nature Communications 12, no. 1 (2021): 187.

[129] B. Wang, X. Jiang, M. Cao, et al., “Altered Fecal Microbiota Correlates With Liver Biochemistry in Nonobese Patients With Non-alcoholic Fatty Liver Disease,” Scientific Reports 6 (2016): 32002.

[130] T. G. Oh, S. M. Kim, C. Caussy, et al., “A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis,” Cell Metabolism 32, no. 5 (2020): 901.

[131] L. Hoyles, J.-M. Fernández-Real, M. Federici, et al., “Molecular Phenomics and Metagenomics of Hepatic Steatosis in Non-diabetic Obese Women,” Nature Medicine 24, no. 7 (2018): 1070–1080.

[132] R. Loomba, V. Seguritan, W. Li, et al., “Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease,” Cell Metabolism 25, no. 5 (2017): 1054–1062. e5.

[133] C. Iino, T. Endo, K. Mikami, et al., “Significant Decrease in Faecalibacterium Among Gut Microbiota in Nonalcoholic Fatty Liver Disease: A Large BMI- and Sex-matched Population Study,” Hepatology International 13, no. 6 (2019): 748–756.

[134] H. E. Da Silva, A. Teterina, E. M. Comelli, et al., “Nonalcoholic Fatty Liver Disease Is Associated With Dysbiosis Independent of Body Mass Index and Insulin Resistance,” Scientific Reports 8, no. 1 (2018): 1466.

[135] C. Özkul, M. Yalınay, T. Karakan, and G. Yılmaz, “Determination of Certain Bacterial Groups in Gut Microbiota and Endotoxin Levels in Patients With Nonalcoholic Steatohepatitis,” The Turkish Journal of Gastroenterology: The Official Journal of Turkish Society of Gastroenterology 28, no. 5 (2017): 361–369.

[136] X. Zhang, O. O. Coker, E. S. Chu, et al., “Dietary Cholesterol Drives Fatty Liver-associated Liver Cancer by Modulating Gut Microbiota and Metabolites,” Gut 70, no. 4 (2021): 761–774.

[137] A. Monga Kravetz, T. Testerman, B. Galuppo, et al., “Effect of Gut Microbiota and PNPLA3 rs738409 Variant on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Youth,” Journal of Clinical Endocrinology and Metabolism 105, no. 10 (2020): e3575–e3585.

[138] L. Yang, Y. Dai, H. He, et al., “Integrative Analysis of Gut Microbiota and Fecal Metabolites in Metabolic Associated Fatty Liver Disease Patients,” Frontiers in Microbiology 13 (2022): 969757.

[139] E. Nistal, L. E. Sáenz de Miera, M. Ballesteros Pomar, et al., “An Altered Fecal Microbiota Profile in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) Associated With Obesity,” Revista Espanola De Enfermedades Digestivas 111, no. 4 (2019): 275–282.

[140] C. Caussy, A. Tripathi, G. Humphrey, et al., “A Gut Microbiome Signature for Cirrhosis Due to Nonalcoholic Fatty Liver Disease,” Nature Communications 10, no. 1 (2019): 1406.

[141] C. Yang, J. Xu, X. Xu, et al., “Characteristics of Gut Microbiota in Patients With Metabolic Associated Fatty Liver Disease,” Scientific Reports 13, no. 1 (2023): 9988.

[142] N. Lanthier, J. Rodriguez, M. Nachit, et al., “Microbiota Analysis and Transient Elastography Reveal New Extra-hepatic Components of Liver Steatosis and Fibrosis in Obese Patients,” Scientific Reports 11, no. 1 (2021): 659.

[143] N. N. You, J. L. Xu, L. Y. Wang, et al., “Fecal Fungi Dysbiosis in Nonalcoholic Fatty Liver Disease,” Obesity 29, no. 2 (2021): 350–358.

[144] M. Demir, S. Lang, P. Hartmann, et al., “The Fecal Mycobiome in Non-alcoholic Fatty Liver Disease,” Journal of Hepatology 76, no. 4 (2022): 788–799.

[145] S. Lang, M. Demir, A. Martin, et al., “Intestinal Virome Signature Associated with Severity of Nonalcoholic Fatty Liver Disease,” Gastroenterology 159, no. 5 (2020): 1839–1852.

[146] C. Niu, Y. Tu, Q. Jin, et al., “Mapping the human Oral and Gut Fungal Microbiota in Patients With Metabolic Dysfunction-associated Fatty Liver Disease,” Frontiers in Cellular and Infection Microbiology 13 (2023): 1157368.

[147] H. Leung, X. Long, Y. Ni, et al., “Risk Assessment With Gut Microbiome and Metabolite Markers in NAFLD Development,” Science Translational Medicine 14, no. 648 (2022): eabk0855.

[148] Q. Zhai, H. Wu, S. Zheng, et al., “Association Between Gut Microbiota and NAFLD/NASH: A Bidirectional Two-sample Mendelian Randomization Study,” Frontiers in Cellular and Infection Microbiology 13 (2023): 1294826.

[149] X. Dai, K. Jiang, X. Ma, et al., “Mendelian Randomization Suggests a Causal Relationship Between Gut Microbiota and Nonalcoholic Fatty Liver Disease in Humans,” Medicine 103, no. 12 (2024): e37478.

[150] C. Yang, J. Wu, L. Yang, et al., “Altered Gut Microbial Profile Accompanied by Abnormal Short Chain Fatty Acid Metabolism Exacerbates Nonalcoholic Fatty Liver Disease Progression,” Scientific Reports 14, no. 1 (2024): 22385.

[151] Y. Li, X. Liang, Y. Lyu, et al., “Association Between the Gut Microbiota and Nonalcoholic Fatty Liver Disease: A Two-sample Mendelian Randomization Study,” Digestive and Liver Disease 55, no. 11 (2023): 1464–1471.

[152] T. Pan, L. Su, Y. Zhang, F. Yi, and Y. Chen, “Impact of Gut Microbiota on Nonalcoholic Fatty Liver Disease: Insights From a Leave-one-out Cross-validation Study,” Frontiers in Microbiology 14 (2023): 1320279.

[153] M. Borges-Canha, J. Centelles-Lodeiro, A. R. Leite, et al., “Gut Dysbiosis Is Linked to Severe Steatosis and Enhances Its Diagnostic Performance in MASLD,” eGastroenterology 3, no. 3 (2025): e100204.

[154] N. G. Vallianou, D. Kounatidis, S. Psallida, et al., “NAFLD/MASLD and the Gut-Liver Axis: From Pathogenesis to Treatment Options,” Metabolites 14, no. 7 (2024): 366.

[155] A. Albillos, A. De Gottardi, and M. Rescigno, “The Gut-liver Axis in Liver Disease: Pathophysiological Basis for Therapy,” Journal of Hepatology 72, no. 3 (2020): 558–577.

[156] M. H. Kim, S. G. Kang, J. H. Park, M. Yanagisawa, and C. H. Kim, “Short-chain Fatty Acids Activate GPR41 and GPR43 on Intestinal Epithelial Cells to Promote Inflammatory Responses in Mice,” Gastroenterology 145, no. 2 (2013): 396–406. e10.

[157] B. Dalile, L. Van Oudenhove, B. Vervliet, and K. Verbeke, “The Role of Short-chain Fatty Acids in Microbiota–gut–brain Communication,” Nature Reviews Gastroenterology & Hepatology 8, no. 8 (2019): 461–478.

[158] Z. Wang, X. X. Zhang, L. L. Zhu, et al., “Inulin Alleviates Inflammation of Alcoholic Liver Disease via SCFAs-inducing Suppression of M1 and Facilitation of M2 Macrophages in Mice,” International Immunopharmacology 78 (2020): 106062.

[159] M. Zhou, L. J. Johnston, C. Wu, and X. Ma, “Gut Microbiota and Its Metabolites: Bridge of Dietary Nutrients and Obesity-related Diseases,” Critical Reviews in Food Science and Nutrition 63, no. 18 (2023): 3236–3253.

[160] W. Liu, X. Luo, J. Tang, et al., “A Bridge for Short-chain Fatty Acids to Affect Inflammatory Bowel Disease, Type 1 Diabetes, and Non-alcoholic Fatty Liver Disease Positively: By Changing Gut Barrier,” European Journal of Nutrition 60, no. 5 (2021): 2317–2330.

[161] R. P. Rai, Y. Liu, S. S. Iyer, et al., “Blocking Integrin α4β7-mediated CD4 T Cell Recruitment to the Intestine and Liver Protects Mice From Western Diet-induced Non-alcoholic Steatohepatitis,” Journal of Hepatology 73, no. 5 (2020): 1013–1022.

[162] C. Sun, C. Qiu, Y. Zhang, et al., “Lactiplantibacillus Plantarum NKK20 Alleviates High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease in Mice Through Regulating Bile Acid Anabolism,” Molecules (Basel, Switzerland) 28, no. 1 (2023): 4042.

[163] D. Zhou, Q. Pan, F.-Z. Xin, et al., “Sodium Butyrate Attenuates High-fat Diet-induced Steatohepatitis in Mice by Improving Gut Microbiota and Gastrointestinal Barrier,” World Journal of Gastroenterology 23, no. 1 (2017): 60–75.

[164] S. Zhai, S. Qin, L. Li, L. Zhu, Z. Zou, and L. Wang, “Dietary Butyrate Suppresses Inflammation Through Modulating Gut Microbiota in High-fat Diet-fed Mice,” Fems Microbiology Letters 366, no. 13 (2019): fnz153.

[165] X. Gong, Q. Zhang, Y. Ruan, M. Hu, Z. Liu, and L. Gong, “Chronic Alcohol Consumption Increased Bile Acid Levels in Enterohepatic Circulation and Reduced Efficacy of Irinotecan,” Alcohol and Alcoholism 55, no. 3 (2020): 264–277.

[166] M. W. Jiang, F. Y. Li, Y. H. Liu, et al., “Probiotic-derived Nanoparticles Inhibit ALD Through Intestinal miR194 Suppression and Subsequent FXR Activation,” Hepatology 77, no. 4 (2023): 1164–1180.

[167] E. Smirnova, M. D. Muthiah, N. Narayan, et al., “Metabolic Reprogramming of the Intestinal Microbiome With Functional Bile Acid Changes Underlie the Development of NAFLD,” Hepatology 76, no. 6 (2022): 1811–1824.

[168] S. L. Collins, J. G. Stine, J. E. Bisanz, C. D. Okafor, and A. D. Patterson, “Bile Acids and the Gut Microbiota: Metabolic Interactions and Impacts on Disease,” Nature Reviews Microbiology 21, no. 4 (2023): 236–247.

[169] Y. Wang, S. Chen, B. Ye, et al., “Acalabrutinib Alleviates Metabolic Dysfunction–associated Steatotic Liver Disease by Regulating Bile Acid Metabolism,” The International Journal of Biochemistry & Cell Biology 185 (2025): 106786.

[170] X. Su, Y. Gao, and R. Yang, “Gut Microbiota Derived Bile Acid Metabolites Maintain the Homeostasis of Gut and Systemic Immunity,” Frontiers in Immunology 14 (2023): 1127743.

[171] K. Yu, Q. Li, X. Sun, et al., “Bacterial Indole-3-lactic Acid Affects Epithelium-macrophage Crosstalk to Regulate Intestinal Homeostasis,” Proceedings of the National Academy of Sciences of the United States of America 120, no. 45 (2023): e2309032120.

[172] Z.-H. Zhao, F.-Z. Xin, Y. Q. Xue, et al., “Indole-3-propionic Acid Inhibits Gut Dysbiosis and Endotoxin Leakage to Attenuate Steatohepatitis in Rats,” Experimental & Molecular Medicine 51, no. 9 (2019): 1–14.

[173] E. E. Alexeev, J. M. Lanis, D. J. Kao, et al., “Microbiota-derived Indole Metabolites Promote human and Murine Intestinal Homeostasis Through Regulation of Interleukin-10 Receptor,” American Journal of Pathology 188, no. 5 (2018): 1183–1194.

[174] L. Ma, H. Li, J. Hu, et al., “Indole Alleviates Diet-Induced Hepatic Steatosis and Inflammation in a Manner Involving Myeloid Cell 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3,” Hepatology 72, no. 4 (2020): 1191–1203.

[175] S. Zeng, E. Rosati, C. Saggau, et al., “Candida albicans-specific Th17 Cell-mediated Response Contributes to Alcohol-associated Liver Disease,” Cell Host & Microbe 31, no. 3 (2023): 389–404. e7.

[176] S. L. Zeng and B. Schnabl, “Gut Mycobiome Alterations and Implications for Liver Diseases,” Plos Pathogens 20, no. 8 (2024): e1012377.

[177] L. Kasper, A. König, P.-A. Koenig, et al., “The Fungal Peptide Toxin candidalysin Activates the NLRP3 Inflammasome and Causes Cytolysis in Mononuclear Phagocytes,” Nature Communications 9, no. 1 (2018): 4260.

[178] A. R. Mridha, A. Wree, A. A. B. Robertson, et al., “NLRP3 inflammasome Blockade Reduces Liver Inflammation and Fibrosis in Experimental NASH in Mice,” Journal of Hepatology 66, no. 5 (2017): 1037–1046.

[179] M.-X. Wang, W. Luo, L. Ye, et al., “Dectin-1 Plays a Deleterious Role in High Fat Diet-induced NAFLD of Mice Through Enhancing Macrophage Activation,” Acta Pharmacologica Sinica 44, no. 1 (2023): 120–132.

[180] K. A. J. Mitchelson, T. T. T. Tran, E. T. Dillon, et al., “Yeast β-glucan Improves Insulin Sensitivity and Hepatic Lipid Metabolism in Mice Humanized With Obese Type 2 Diabetic Gut Microbiota,” Molecular Nutrition & Food Research 66, no. 22 (2022): 2100819.

[181] N. Ikewaki, G. A. Levy, G. Kurosawa, et al., “Hepatoprotective Effects of Aureobasidium Pullulans Derived β 1,3-1,6 Glucans in a Murine Model of Non-alcoholic Steatohepatitis,” Journal of Clinical and Experimental Hepatology 12, no. 6 (2022): 1428–1437.

[182] S.-S. Sun, K. Wang, K. Ma, L. Bao, and H.-W. Liu, “An Insoluble Polysaccharide From the Sclerotium of Poria cocos Improves Hyperglycemia, Hyperlipidemia and Hepatic Steatosis in Ob/Ob Mice via Modulation of Gut Microbiota,” Chinese Journal of Natural Medicines 17, no. 1 (2019): 3–14.

[183] C. S. Lieber, “Alcoholic Fatty Liver: Its Pathogenesis and Mechanism of Progression to Inflammation and Fibrosis,” Alcohol 34, no. 1 (2004): 9–19.

[184] A. J. Nowak and B. Relja, “The Impact of Acute or Chronic Alcohol Intake on the NF-κB Signaling Pathway in Alcohol-related Liver Disease,” International Journal of Molecular Sciences 21, no. 24 (2020): 9407.

[185] H. Jaeschke and T. D. S. Hasegawa, “Role of Neutrophils in Acute Inflammatory Liver Injury,” Liver International 26, no. 8 (2006): 912–919.

[186] K. Imajo, K. Fujita, M. Yoneda, et al., “Hyperresponsivity to Low-dose Endotoxin During Progression to Nonalcoholic Steatohepatitis Is Regulated by Leptin-mediated Signaling,” Cell Metabolism 16, no. 1 (2012): 44–54.

[187] L. Chen, L. Zhang, H. Hua, L. Liu, Y. Mao, and R. Wang, “Interactions Between Toll-Like Receptors Signaling Pathway and Gut Microbiota in Host Homeostasis,” Immunity, Inflammation and Disease 12, no. 7 (2024): e1356.

[188] M. E. Shaker, “The Contribution of Sterile Inflammation to the Fatty Liver Disease and the Potential Therapies,” Biomedicine & Pharmacotherapy 148 (2022): 112789.

[189] J. Yu, C. Zhu, X. Wang, et al., “Hepatocyte TLR4 Triggers Inter-hepatocyte Jagged1/Notch Signaling to Determine NASH-induced Fibrosis,” Science Translational Medicine 13, no. 599 (2021): eabe1692.

[190] Y. Zhang, W. Jiang, J. Xu, et al., “E. coli NF73-1 Isolated from NASH Patients Aggravates NAFLD in Mice by Translocating into the Liver and Stimulating M1 Polarization,” Frontiers in Cellular and Infection Microbiology 10 (2020): 535940.

[191] H. Gao, Y. Jiang, G. Zeng, et al., “Cell-to-cell and Organ-to-organ Crosstalk in the Pathogenesis of Alcohol-associated Liver Disease,” eGastroenterology 2, no. 4 (2024): e100104.

[192] M. Dukić, T. Radonjić, I. Jovanović, et al., “Alcohol, Inflammation, and Microbiota in Alcoholic Liver Disease,” International Journal of Molecular Sciences 24, no. 4 (2023): 3735.

[193] Y. K. Guan, B. Peiffer, D. C. Feng, et al., “IL-8+ Neutrophils Drive Inexorable Inflammation in Severe Alcohol-associated hepatitis,” Journal of Clinical Investigation 134, no. 9 (2024): e178616.

[194] D. Rousseau, S. Bonnafous, F. Soysouvanh, et al., “CD44 in Myeloid Cells Is a Major Driver of Liver Inflammation and Injury in Alcohol-associated Liver Disease,” Hepatology 82, no. 5 (2025): 1211–1228.

[195] C. Gao, S. G. Wang, X. Y. Xie, et al., “Single-cell Profiling of Intrahepatic Immune Cells Reveals an Expansion of Tissue-resident Cytotoxic CD4+ T Lymphocyte Subset Associated With Pathogenesis of Alcoholic-associated Liver Diseases,” Cellular and Molecular Gastroenterology and Hepatology 19, no. 2 (2025): 101411.

[196] L. Maccioni, Y. K. Guan, M. Kim, et al., “Opposite Regulation of Intestinal and Intrahepatic CD8⁺ T Cells Controls Alcohol-associated Liver Disease Progression,” Gut 74, no. 8 (2025): 1308–1320.

[197] L. Maccioni, A. Loriot, J. Dewulf, et al., “Duodenal CD8+ T Resident Memory Cell Apoptosis Contributes to Gut Barrier Dysfunction and Microbial Translocation in Early Alcohol-associated Liver Disease in Humans,” Alimentary Pharmacology & Therapeutics 56, no. 6 (2022): 1055–1070.

[198] I. Marrero, I. Maricic, T. R. Morgan, et al., “Differential Activation of Unconventional T Cells, Including iNKT Cells, in Alcohol-Related Liver Disease,” Alcoholism, Clinical and Experimental Research 44, no. 5 (2020): 1061–1074.

[199] Y. Zhu, X. Z. Wang, L. J. Zhu, et al., “Lactobacillus Rhamnosus GG Combined With Inosine Ameliorates Alcohol-induced Liver Injury Through Regulation of Intestinal Barrier and Treg/Th1 Cells,” Toxicology and Applied Pharmacology 439 (2022): 115923.

[200] A. N. Bienia, W. Sodolski, and E. Luchowska, “The Effect of Chronic Alcohol Abuse on Gastric and Duodenal Mucosa,” Annales Universitatis Mariae Curie-Sklodowska - Sectio D Medicina 57, no. 2 (2002): 570–582.

[201] D. Sibley and T. R. Jerrells, “Alcohol Consumption by C57BL/6 Mice Is Associated With Depletion of Lymphoid Cells From the Gut-associated Lymphoid Tissues and Altered Resistance to Oral Infections With Salmonella Typhimurium,” Journal of Infectious Diseases 182, no. 2 (2000): 482–489.

[202] E. Slevin, L. Baiocchi, N. Wu, et al., “Kupffer Cells: Inflammation Pathways and Cell-Cell Interactions in Alcohol-Associated Liver Disease,” American Journal of Pathology 190, no. 11 (2020): 2185–2193.

[203] K. Kazankov, S. M. D. Jørgensen, K. L. Thomsen, et al., “The Role of Macrophages in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis,” Nature Reviews Gastroenterology & Hepatology 16, no. 3 (2019): 145–159.

[204] Y. Wen, J. Lambrecht, C. Ju, and F. Tacke, “Hepatic Macrophages in Liver Homeostasis and Diseases-diversity, Plasticity and Therapeutic Opportunities,” Cellular & Molecular Immunology 18, no. 1 (2021): 45–56.

[205] M. Nagashimada and M. Honda, “Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics,” International Journal of Molecular Sciences 22, no. 15 (2021): 8008.

[206] C. Wang, C. Ma, L. Gong, et al., “Macrophage Polarization and Its Role in Liver Disease,” Frontiers in Immunology 12 (2021): 803037.

[207] C. Rosales, “Neutrophil: A Cell With Many Roles in Inflammation or Several Cell Types?,” Frontiers in Physiology 9 (2018): 113.

[208] I. Kourtzelis, I. Mitroulis, J. von Renesse, G. Hajishengallis, and T. Chavakis, “From Leukocyte Recruitment to Resolution of Inflammation: The Cardinal Role of Integrins,” Journal of Leukocyte Biology 102, no. 3 (2017): 677–683.

[209] E. J. M. Toonen, A.-M. Mirea, C. J. Tack, et al., “Activation of Proteinase 3 Contributes to Non-alcoholic Fatty Liver Disease (NAFLD) and Insulin Resistance,” Molecular Medicine 22 (2016): 202–214.

[210] A.-M. Mirea, E. J. M. Toonen, I. van den Munckhof, et al., “Increased Proteinase 3 and Neutrophil Elastase Plasma Concentrations Are Associated With Non-alcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes,” Molecular Medicine 25, no. 1 (2019): 16.

[211] D. W. Ma, J. Ha, K. S. Yoon, I. Kang, T. G. Choi, and S. S. Kim, “Innate Immune System in the Pathogenesis of Non-Alcoholic Fatty Liver Disease,” Nutrients 15, no. 9 (2023): 2068.

[212] M. Monserrat-Mesquida, M. Quetglas-Llabrés, M. Abbate, et al., “Oxidative Stress and Pro-Inflammatory Status in Patients With Non-Alcoholic Fatty Liver Disease,” Antioxidants (Basel) 9, no. 8 (2020): 759.

[213] L. Petagine, M. G. Zariwala, and V. B. Patel, “Non-alcoholic Fatty Liver Disease: Immunological Mechanisms and Current Treatments,” World Journal of Gastroenterology 29, no. 32 (2023): 4831–4850.

[214] S. Bruzzì, S. Sutti, G. Giudici, et al., “B2-Lymphocyte Responses to Oxidative Stress-derived Antigens Contribute to the Evolution of Nonalcoholic Fatty Liver Disease (NAFLD),” Free Radical Biology and Medicine 124 (2018): 249–259.

[215] S. Talukdar, D. Y. Oh, G. Bandyopadhyay, et al., “Neutrophils Mediate Insulin Resistance in Mice Fed a High-fat Diet Through Secreted Elastase,” Nature Medicine 18, no. 9 (2012): 1407–1412.

[216] B. Gao and H. Tsukamoto, “Inflammation in Alcoholic and Nonalcoholic Fatty Liver Disease: Friend or Foe?,” Gastroenterology 150, no. 8 (2016): 1704–1709.

[217] R. Gallego-Durán, R. Montero-Vallejo, D. Maya-Miles, et al., “Analysis of Common Pathways and Markers from Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases,” Frontiers in Immunology 12 (2021): 667354.

[218] H. Tilg, T. E. Adolph, M. Dudek, and P. Knolle, “Non-alcoholic Fatty Liver Disease: The Interplay Between Metabolism, Microbes and Immunity,” Nature Metabolism 3, no. 12 (2021): 1596–1607.

[219] F. Barrow, S. Khan, G. Fredrickson, et al., “Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH through Innate and Adaptive Signaling,” Hepatology 74, no. 2 (2021): 704–722.

[220] K. S. K. Sawada, H. Chung, S. Softic, M. E. Moreno-Fernandez, and S. Divanovic, “The Bidirectional Immune Crosstalk in Metabolic Dysfunction-associated Steatotic Liver Disease,” Cell Metabolism 35, no. 11 (2023): 1852–1871.

[221] K. J. Waller, H. Saihi, W. Li, et al., “Single-cell Phenotypes of Peripheral Blood Immune Cells in Early and Late Stages of Non-alcoholic Fatty Liver Disease,” Clinical and Molecular Hepatology 29, no. 2 (2023): 417–432.

[222] S. W. Zhang, X. K. Gang, S. Yang, et al., “The Alterations in and the Role of the Th17/Treg Balance in Metabolic Diseases,” Frontiers in Immunology 12 (2021): 678355.

[223] F. Riaz, P. Wei, and F. Pan, “Fine-tuning of Regulatory T Cells Is Indispensable for the Metabolic Steatosis-related Hepatocellular Carcinoma: A Review,” Frontiers in Cell and Developmental Biology 10 (2022): 949603.

[224] H. H. Xu, Z. H. Wu, J. F. Qin, et al., “Stressed Hepatocyte Sustains Alcohol-associated hepatitis Progression by Producing Leukocyte Cell-derived Chemotaxin 2,” Gut 74, no. 8 (2025): 1321–1334.

[225] E. A. Mutlu, P. M. Gillevet, H. Rangwala, et al., “Colonic Microbiome Is Altered in Alcoholism,” American Journal of Physiology Gastrointestinal and Liver Physiology 302, no. 9 (2012): G966–978.

[226] A. Tripathi, J. Debelius, D. A. Brenner, et al., “The Gut–liver Axis and the Intersection With the Microbiome,” Nature Reviews Gastroenterology & Hepatology 15, no. 7 (2018): 397–411.

[227] N. Roy, N. Nadda, H. Kumar, et al., “Pattern Recognition Receptor CD14 Gene Polymorphisms in Alcohol Use Disorder Patients and Its Influence on Liver Disease Susceptibility,” Frontiers in Immunology 13 (2022): 975027.

[228] J. Petrasek, S. S. Bala, T. Csak, et al., “IL-1 Receptor Antagonist Ameliorates Inflammasome-dependent Alcoholic Steatohepatitis in Mice,” Journal of Clinical Investigation 122, no. 10 (2012): 3476–3489.

[229] I. D. Vachliotis and S. A. Polyzos, “The Role of Tumor Necrosis Factor-alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease,” Current Obesity Reports 12, no. 3 (2023): 191–206.

[230] A. Wieckowska, B. G. Papouchado, Z. Li, R. Lopez, N. N. Zein, and A. E. Feldstein, “Increased Hepatic and Circulating Interleukin-6 Levels in human Nonalcoholic Steatohepatitis,” American Journal of Gastroenterology 103, no. 6 (2008): 1372–1379.

[231] M. Yoneda, H. Mawatari, K. Fujita, et al., “High-sensitivity C-reactive Protein Is an Independent Clinical Feature of Nonalcoholic Steatohepatitis (NASH) and Also of the Severity of Fibrosis in NASH,” Journal of Gastroenterology 42, no. 7 (2007): 573–582.

[232] T. Inamine and B. Schnabl, “Immunoglobulin A and Liver Diseases,” Journal of Gastroenterology 53, no. 6 (2018): 691–700.

[233] S. McPherson, E. Henderson, A. D. Burt, C. P. Day, and Q. M. Anstee, “Serum Immunoglobulin Levels Predict Fibrosis in Patients With Non-alcoholic Fatty Liver Disease,” Journal of Hepatology 60, no. 5 (2014): 1055–1062.

[234] S. Shalapour, X.-J. Lin, I. N. Bastian, et al., “Inflammation-induced IgA+ Cells Dismantle Anti-liver Cancer Immunity,” Nature 551, no. 7680 (2017): 340–345.

[235] E. Kotsiliti, V. Leone, S. Schuehle, et al., “Intestinal B Cells License Metabolic T-cell Activation in NASH Microbiota/Antigen-independently and Contribute to Fibrosis by IgA-FcR Signalling,” Journal of Hepatology 79, no. 2 (2023): 296–313.

[236] T. M. D. Nguyen, “Adiponectin: Role in Physiology and Pathophysiology,” International Journal of Preventive Medicine 11 (2020): 136.

[237] C. Finelli, “What Is the Role of Adiponectin in Obesity Related Non-alcoholic Fatty Liver Disease?,” World Journal of Gastroenterology 19, no. 6 (2013): 802.

[238] T. E. Silva, G. Colombo, and L. L. Schiavon, “Adiponectin: A Multitasking Player in the Field of Liver Diseases,” Diabetes & Metabolism 40, no. 2 (2014): 95–107.

[239] T. Gamberi, F. Magherini, A. Modesti, and T. Fiaschi, “Adiponectin Signaling Pathways in Liver Diseases,” Biomedicines 6, no. 2 (2018): 52.

[240] Z. Dong, Q. Zhuang, X. Ye, et al., “Adiponectin Inhibits NLRP3 Inflammasome Activation in Nonalcoholic Steatohepatitis via AMPK-JNK/ErK1/2-NFκB/ROS Signaling Pathways,” Frontiers in Medicine (Lausanne) 7 (2020): 546445.

[241] J. Qin, W. Zhu, and W. Zhou, “Navigating the Paradox of IL-22: Friend or Foe in Hepatic Health?,” Journal of Gastroenterology and Hepatology 40, no. 6 (2025): 1393–1408.

[242] Z. Xing, Y. Wu, and N. Liu, “IL-22 Alleviates the Fibrosis of Hepatic Stellate Cells via the Inactivation of NLRP3 Inflammasome Signaling,” Experimental and Therapeutic Medicine 22, no. 4 (2021): 1088.

[243] X. Kong, D. Feng, H. Wang, et al., “Interleukin-22 Induces Hepatic Stellate Cell Senescence and Restricts Liver Fibrosis in Mice,” Hepatology 56, no. 3 (2012): 1150–1159.

[244] J.-H. Oh, K. L. Schueler, D. S. Stapleton, et al., “Secretion of Recombinant Interleukin-22 by Engineered Lactobacillus Reuteri Reduces Fatty Liver Disease in a Mouse Model of Diet-Induced Obesity,” mSphere 5, no. 3 (2020): e00183–20.

[245] W. J. Zai, W. Chen, Z. M. Wu, et al., “Targeted Interleukin-22 Gene Delivery in the Liver by Polymetformin and Penetratin-based Hybrid Nanoparticles to Treat Nonalcoholic Fatty Liver Disease,” ACS Applied Materials & Interfaces 11, no. 5 (2019): 4842–4857.

[246] Y. Duan, X. Pan, J. Luo, et al., “Association of Inflammatory Cytokines with Non-Alcoholic Fatty Liver Disease,” Frontiers in Immunology 13 (2022): 880298.

[247] E. H. Steen, X. Y. Wang, S. Balaji, M. J. Butte, P. L. Bollyky, and S. G. Keswani, “The Role of the Anti-inflammatory Cytokine Interleukin-10 in Tissue Fibrosis,” Advances in Wound Care 9, no. 4 (2020): 184–198.

[248] P. Horn and F. Tacke, “Key Takeaways From the Updated Multidisciplinary european MASLD Guidelines,” eGastroenterology 3, no. 2 (2025): e100196.

[249] H. Shen, L. Zhou, H. Zhang, et al., “Dietary fiber Alleviates Alcoholic Liver Injury via Bacteroides Acidifaciens and Subsequent Ammonia Detoxification,” Cell Host & Microbe 32, no. 8 (2024): 1331–1346. e6.

[250] G. N. Li, H. Q. Chen, F. Shen, et al., “Targeting Hepatic Serine-arginine Protein Kinase 2 Ameliorates Alcohol-associated Liver Disease by Alternative Splicing Control of Lipogenesis,” Hepatology 78, no. 5 (2023): 1506–1524.

[251] H.-X. Bai, Y.-X. Gao, S. Y. Wang, et al., “Structure Characteristics of a Novel Pectic Polysaccharide From Fructus Corni and Its Protective Effect on Alcoholic Fatty Liver,” Carbohydrate Polymers 352 (2025): 123153.

[252] S. Gawrieh, M. Noureddin, N. Loo, et al., “Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-blind Phase 2 Trial,” Hepatology (Baltimore, Md) 74, no. 4 (2021): 1809–1824.

[253] Y. Honda, T. Kessoku, Y. Ogawa, et al., “Pemafibrate, a Novel Selective Peroxisome Proliferator-activated Receptor Alpha Modulator, Improves the Pathogenesis in a Rodent Model of Nonalcoholic Steatohepatitis,” Scientific Reports 7 (2017): 42477.

[254] Y. Sasaki, S. Raza-Iqbal, T. Tanaka, et al., “Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-activated Receptor α Modulator (SPPARMα) Pemafibrate,” International Journal of Molecular Sciences 20, no. 22 (2019): 5682.

[255] A. Morishita, K. Oura, K. Takuma, et al., “Pemafibrate Improves Liver Dysfunction and Non-invasive Surrogates for Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease With Hypertriglyceridemia: A Multicenter Study,” Hepatology International 17, no. 3 (2023): 606–614.

[256] S. M. Francque, P. Bedossa, V. Ratziu, et al., “A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH,” New England Journal of Medicine 385, no. 17 (2021): 1547–1558.

[257] G. Wettstein, J. Luccarini, L. Poekes, et al., “The New-generation Pan-peroxisome Proliferator-activated Receptor Agonist IVA337 Protects the Liver From Metabolic Disorders and Fibrosis,” Hepatology Communications 1, no. 6 (2017): 524–537.

[258] G. Harriman, J. Greenwood, S. Bhat, et al., “Acetyl-CoA Carboxylase Inhibition by ND-630 Reduces Hepatic Steatosis, Improves Insulin Sensitivity, and Modulates Dyslipidemia in Rats,” Proceedings of the National Academy of Sciences of the United States of America 113, no. 13 (2016): E1796–1805.

[259] T. T. Ross, C. Crowley, K. L. Kelly, et al., “Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems,” Cellular and Molecular Gastroenterology and Hepatology 10, no. 4 (2020): 829–851.

[260] A. Ambade, P. Lowe, K. Kodys, et al., “Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-induced Liver Damage, Steatosis, and Inflammation in Mice,” Hepatology 69, no. 3 (2019): 1105–1121.

[261] Y. L. Jin, C. Y. Wang, Z. Q. Meng, et al., “Proanthocyanidins Alleviate Acute Alcohol Liver Injury by Inhibiting Pyroptosis via Inhibiting the ROS-MLKL-CTSB-NLRP3 Pathway,” Phytomedicine 136 (2025): 156268.

[262] P. Qiu, A. Mi, C. Hong, et al., “An Integrated Network Pharmacology Approach Reveals That Ampelopsis Grossedentata Improves Alcoholic Liver Disease via TLR4/NF-κB/MLKL Pathway,” Phytomedicine 132 (2024): 155658.

[263] H. Zhang, Q. Hu, Y. Zhang, et al., “Lachnospiraceae Bacterium Alleviates Alcohol-associated Liver Disease by Enhancing N-acetyl-glutamic Acid Levels and Inhibiting Ferroptosis Through the KEAP1-NRF2 Pathway,” Gut Microbes 17, no. 1 (2025): 2517821.

[264] Q. M. Anstee, D. Concas, H. Kudo, et al., “Impact of Pan-caspase Inhibition in Animal Models of Established Steatosis and Non-alcoholic Steatohepatitis,” Journal of Hepatology 53, no. 3 (2010): 542–550.

[265] F. J. Barreyro, S. Holod, P. V. Finocchietto, et al., “The Pan-caspase Inhibitor Emricasan (IDN-6556) Decreases Liver Injury and Fibrosis in a Murine Model of Non-alcoholic Steatohepatitis,” Liver International 35, no. 3 (2015): 953–966.

[266] R. P. Witek, W. C. Stone, F. G. Karaca, et al., “Pan-caspase Inhibitor VX-166 Reduces Fibrosis in an Animal Model of Nonalcoholic Steatohepatitis,” Hepatology 50, no. 5 (2009): 1421–1430.

[267] J. J. Zhu, Y. Wen, Q. L. Zhang, F. Nie, M. L. Cheng, and X. K. Zhao, “The Monomer TEC of Blueberry Improves NASH by Augmenting tRF-47-mediated Autophagy/Pyroptosis Signaling Pathway,” Journal of translational medicine 20, no. 1 (2022): 128.

[268] S. H. Kim, G. Kim, D. H. Han, et al., “Ezetimibe Ameliorates Steatohepatitis via AMP Activated Protein Kinase-TFEB-mediated Activation of Autophagy and NLRP3 Inflammasome Inhibition,” Autophagy 13, no. 10 (2017): 1767–1781.

[269] Y.-L. Li, X.-Q. Li, Y.-D. Wang, C. Shen, and C.-Y. Zhao, “Metformin Alleviates Inflammatory Response in Non-alcoholic Steatohepatitis by Restraining Signal Transducer and Activator of Transcription 3-mediated Autophagy Inhibition in Vitro and in Vivo,” Biochemical and Biophysical Research Communications 513, no. 1 (2019): 64–72.

[270] S. Ruan, C. Han, Y. Sheng, et al., “Antcin A Alleviates Pyroptosis and Inflammatory Response in Kupffercells of Non-alcoholic Fatty Liver Disease by Targeting NLRP3,” International Immunopharmacology 100 (2021): 108126.

[271] S. Oh, M. Son, K.-A. Byun, et al., “Attenuating Effects of Dieckol on High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease by Decreasing the NLRP3 Inflammasome and Pyroptosis,” Marine Drugs 19, no. 6 (2021): 318.

[272] X. L. Zhang, X. Y. Shang, S. Jin, et al., “Vitamin D Ameliorates High-fat-diet-induced Hepatic Injury via Inhibiting Pyroptosis and Alters Gut Microbiota in Rats,” Archives of Biochemistry and Biophysics 705 (2021): 108894.

[273] T. Chen, Y. Meng, Z. Zhou, et al., “GAS5 protects Against Nonalcoholic Fatty Liver Disease via miR-28a-5p/MARCH7/NLRP3 Axis-mediated Pyroptosis,” Cell Death and Differentiation 30, no. 7 (2023): 1829–1848.

[274] X. Y. Li, T. Wang, X. M. Huang, et al., “Targeting Ferroptosis Alleviates Methionine-choline Deficient (MCD)-diet Induced NASH by Suppressing Liver Lipotoxicity,” Liver International 40, no. 6 (2020): 1378–1394.

[275] Y. Yang, J. Chen, Q. Gao, X. Shan, J. Wang, and Z. Lv, “Study on the Attenuated Effect of Ginkgolide B on Ferroptosis in High Fat Diet Induced Nonalcoholic Fatty Liver Disease,” Toxicology 445 (2020): 152599.

[276] Z. X. Zhu, Y. Zhang, X. H. Huang, et al., “Thymosin Beta 4 Alleviates Non-alcoholic Fatty Liver by Inhibiting Ferroptosis via Up-regulation of GPX4,” European Journal of Pharmacology 908 (2021): 174351.

[277] J.-J. Jiang, G.-F. Zhang, J.-Y. Zheng, J.-H. Sun, and S.-B. Ding, “Targeting Mitochondrial ROS-mediated Ferroptosis by Quercetin Alleviates High-fat Diet-induced Hepatic Lipotoxicity,” Frontiers in Pharmacology 13 (2022): 876550.

[278] H. Chen, D. Li, H. Zhang, et al., “Mechanisms of Copper Metabolism and Cuproptosis: Implications for Liver Diseases,” Frontiers in Immunology 16 (2025): 1633711.

[279] C. Ma, L. Han, Z. Zhu, C. Heng Pang, and G. Pan, “Mineral Metabolism and Ferroptosis in Non-alcoholic Fatty Liver Diseases,” Biochemical Pharmacology 205 (2022): 115242.

[280] W. Tan, J. Zhang, L. Chen, et al., “Copper Homeostasis and Cuproptosis-related Genes: Therapeutic Perspectives in Non-alcoholic Fatty Liver Disease,” Diabetes, Obesity and Metabolism 26, no. 11 (2024): 4830–4845.

[281] Q. Ma, S. Huang, M.-Y. Li, et al., “Dihydromyricetin Regulates the miR-155-5p/SIRT1/VDAC1 Pathway to Promote Liver Regeneration and Improve Alcohol-induced Liver Injury,” Phytomedicine 139 (2025): 156522.

[282] N. M. Gold, Q. C. Ding, Y. Yang, et al., “Therapeutic Potential of Nicotinamide and ABT263 in Alcohol-associated Liver Disease Through Targeting Cellular Senescence,” Medcomm 6, no. 2 (2025): e70086.

[283] D. Lu, Y. Le, J. Ding, X. Dou, W. Mao, and J. Zhu, “CLIC1 Inhibition Protects against Cellular Senescence and Endothelial Dysfunction via the Nrf2/HO-1 Pathway,” Cell Biochemistry and Biophysics 79, no. 2 (2021): 239–252.

[284] Z. Jie, Y. Huan, W. Mengyun, L. Yasha, P. Huafeng, and Y. Ke, “Nrf2 modulates Immunosuppressive Ability and Cellular Senescence of human Umbilical Cord Mesenchymal Stem Cells,” Biochemical and Biophysical Research Communications 526, no. 4 (2020): 1021–1027.

[285] Z. Wang, Z. Chen, Z. Jiang, et al., “Cordycepin Prevents Radiation Ulcer by Inhibiting Cell Senescence via NRF2 and AMPK in Rodents,” Nature Communications 10, no. 1 (2019): 2538.

[286] E. Katsyuba, A. Mottis, M. Zietak, et al., “De Novo NAD+ Synthesis Enhances Mitochondrial Function and Improves Health,” Nature 563, no. 7731 (2018): 354–359.

[287] N. Xie, L. Zhang, W. Gao, et al., “NAD+ Metabolism: Pathophysiologic Mechanisms and Therapeutic Potential,” Signal Transduction and Targeted Therapy 5, no. 1 (2020): 227.

[288] N. Maharajan, C. D. Ganesan, C. Moon, C.-H. Jang, W.-K. Oh, and G.-W. Cho, “Licochalcone D Ameliorates Oxidative Stress-Induced Senescence via AMPK Activation,” International Journal of Molecular Sciences 22, no. 14 (2021): 7324.

[289] M. Foretz, P. C. Even, and B. Viollet, “AMPK Activation Reduces Hepatic Lipid Content by Increasing Fat Oxidation in Vivo,” International Journal of Molecular Sciences 19, no. 9 (2018): 2826.

[290] Y. Colak, O. Ozturk, E. Senates, et al., “SIRT1 as a Potential Therapeutic Target for Treatment of Nonalcoholic Fatty Liver Disease,” Medical Science Monitor 17, no. 5 (2011): HY5–9.

[291] R.-B. Ding, J. Bao, and C.-X. Deng, “Emerging Roles of SIRT1 in Fatty Liver Diseases,” International Journal of Biological Sciences 13, no. 7 (2017): 852–867.

[292] L. Y. Chen, P. C. Yang, L. L. Hu, L. Yang, H. K. Chu, and X. H. Hou, “Modulating Phenylalanine Metabolism by L. acidophilus Alleviates Alcohol-related Liver Disease Through Enhancing Intestinal Barrier Function,” Cell & Bioscience 13, no. 1 (2023): 24.

[293] H. Liu, X. Kang, X. Yang, et al., “Compound Probiotic Ameliorates Acute Alcoholic Liver Disease in Mice by Modulating Gut Microbiota and Maintaining Intestinal Barrier,” Probiotics and Antimicrobial Proteins 15, no. 1 (2023): 185–201.

[294] Y.-Y. Chi, J.-Y. Xiang, H.-M. Li, et al., “Schisandra chinensis Polysaccharide Prevents Alcohol-associated Liver Disease in Mice by Modulating the Gut Microbiota-tryptophan Metabolism-AHR Pathway Axis,” International Journal of Biological Macromolecules 282, no. Pt 2 (2024): 136843.

[295] R. Yin, T. Wang, J. Sun, et al., “Postbiotics From lactobacillus Johnsonii Activates Gut Innate Immunity to Mitigate Alcohol-associated Liver Disease,” Advanced science (Weinheim, Baden-Württemberg, Germany) 12, no. 2 (2025): e2405781.

[296] J. Wolstenholme, “Gut-liver-brain Axis and Alcohol Use Disorder: Treatment Potential of Fecal Microbiota Transplantation,” Alcohol Research: Current Reviews 44, no. 1 (2024): 1.

[297] Y. Zhang, P. F. Li, B. Chen, and R. P. Zheng, “Therapeutic Effects of Fecal Microbial Transplantation on Alcoholic Liver Injury in Rat Models,” Clinics and Research in Hepatology and Gastroenterology 48, no. 9 (2024): 102478.

[298] H. B. Zhang, C. Y. Li, L. Han, et al., “MUP1 mediates Urolithin a Alleviation of Chronic Alcohol-related Liver Disease via Gut-microbiota-liver Axis,” Gut Microbes 16, no. 1 (2024): 2367342.

[299] H. B. Zhang, W. X. Zhou, P. Gao, et al., “Ellagic Acid Protects Against Alcohol-related Liver Disease by Modulating the Hepatic Circadian Rhythm Signaling Through the Gut Microbiota–NPAS2 Axis,” Journal of Agricultural and Food Chemistry 72, no. 45 (2024): 25103–25117.

[300] R. N. Helsley, T. Miyata, A. Kadam, et al., “Gut Microbial Trimethylamine Is Elevated in Alcohol-associated hepatitis and Contributes to Ethanol-induced Liver Injury in Mice,” Elife 11 (2022): e76554.

[301] T. Hendrikx, Y. Duan, Y. Wang, et al., “Bacteria Engineered to Produce IL-22 in Intestine Induce Expression of REG3G to Reduce Ethanol-induced Liver Disease in Mice,” Gut 68, no. 8 (2019): 1504–1515.

[302] T. Kouno, S. L. Zeng, Y. H. Wang, et al., “Engineered Bacteria Producing Aryl-hydrocarbon Receptor Agonists Protect Against Ethanol-induced Liver Disease in Mice,” Alcohol: Clinical & Experimental Research 47, no. 5 (2023): 856–867.

[303] J. P. Arab, T. S. Sehrawat, D. A. Simonetto, et al., “An Open-Label, Dose-Escalation Study to Assess the Safety and Efficacy of IL-22 Agonist F-652 in Patients with Alcohol-associated Hepatitis,” Hepatology 72, no. 2 (2020): 441.

[304] D. Yang, X. Wei, B. Zhang, et al., “Probiotics Protect Against Hepatic Steatosis in Tris (2-chloroethyl) Phosphate-induced Metabolic Disorder of Mice via FXR Signaling,” Food and Chemical Toxicology 169 (2022): 113440.

[305] M. J. Sáez-Lara, C. Robles-Sanchez, F. J. Ruiz-Ojeda, J. Plaza-Diaz, and A. Gil, “Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials,” International Journal of Molecular Sciences 17, no. 6 (2016): 928.

[306] Y. Tian, Q. Xu, Z. Wu, et al., “Ameliorating Effect of Bifidobacterium Breve CM02-09T on High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Mice,” Faseb Journal 39, no. 16 (2025): e70957.

[307] Z. Li, W. Gao, H. Yuan, et al., “Suppression of Intestinal Ticam1 Ameliorated MASH via Akkermansia Muciniphila QAA37749.1 Mediated Betaine Transformation,” Biochimica et Biophysica Acta: Molecular Basis of Disease 1871, no. 1 (2025): 167571.

[308] J. Zhu, Y. Chen, Y. Han, and J. Li, “Mechanism of Huanglian Wendan Decoction in Ameliorating Non-alcoholic Fatty Liver Disease via Modulating Gut Microbiota-mediated Metabolic Reprogramming and Activating the LKB1/AMPK Pathway,” PLoS ONE 20, no. 9 (2025): e0331303.

[309] Y. Xiao, M. Yang, M. Cai, H. Zhang, K. Hu, and Y. Duan, “EGCG and Taurine Synergistically Ameliorate Lipid Metabolism Disorder by Modulating Gut Microbiota and PPARα/FAS Signaling Pathway,” Nutrients 17, no. 16 (2025): 2595.

[310] H. C.-H. Lau, X. Zhang, and J. Yu, “Gut Microbiome in Metabolic Dysfunction-associated Steatotic Liver Disease and Associated Hepatocellular Carcinoma,” Nature Reviews Gastroenterology & hepatology 22, no. 9 (2025): 619–638.

[311] N. Lanthier and N. Delzenne, “Targeting the Gut Microbiome to Treat Metabolic Dysfunction-associated Fatty Liver Disease: Ready for Prime Time?,” Cells 11, no. 17 (2022): 2718.

[312] E. Bellucci, F. Chiereghin, F. Pacifici, et al., “Novel Therapeutic Approaches Based on the Pathological Role of Gut Dysbiosis on the Link Between Nonalcoholic Fatty Liver Disease and Insulin Resistance,” European Review for Medical and Pharmacological Sciences 27, no. 5 (2023): 1921–1944.

[313] C. Airola, A. Severino, S. Porcari, et al., “Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy,” Antibiotics (Basel) 12, no. 5 (2023): 868.

[314] O. E. Apalowo, G. A. Adegoye, and T. M. Obuotor, “Microbial-Based Bioactive Compounds to Alleviate Inflammation in Obesity,” Current Issues in Molecular Biology 46, no. 3 (2024): 1810–1831.

[315] L. Craven, A. Rahman, S. Nair Parvathy, et al., “Allogenic Fecal Microbiota Transplantation in Patients with Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial,” American Journal of Gastroenterology 115, no. 7 (2020): 1055–1065.

[316] Y. Duan, H. Chu, K. Brandl, et al., “CRIg on Liver Macrophages Clears Pathobionts and Protects Against Alcoholic Liver Disease,” Nature Communications 12, no. 1 (2021): 7172.

[317] N. Szóstak, M. Figlerowicz, and A. Philips, “The Emerging Role of the Gut Mycobiome in Liver Diseases,” Gut Microbes 15, no. 1 (2023): 2211922.

[318] L. Fu, B. Yokus, B. Gao, and P. Pacher, “An Update on IL-22 Therapies in Alcohol-Associated Liver Disease and beyond,” American Journal of Pathology (2025). S0002-9440(25)00117-8.

[319] R. C. Yue, X. Y. Wei, L. Y. Hao, et al., “Promoting Intestinal Antimicrobial Defense and Microbiome Symbiosis Contributes to IL-22-mediated Protection Against Alcoholic hepatitis in Mice,” Frontiers in Immunology 14 (2023): 1289356.

[320] D. Xu, W. Zhao, Y. Feng, X. Wen, H. Liu, and J. Ping, “Pentoxifylline Attenuates Nonalcoholic Fatty Liver by Inhibiting Hepatic Macrophage Polarization to the M1 Phenotype,” Phytomedicine 106 (2022): 154368.

[321] X. Y. Dong, Y. T. Feng, D. Q. Xu, et al., “Targeting Macrophagic 17β-HSD7 by Fenretinide for the Treatment of Nonalcoholic Fatty Liver Disease,” Acta Pharmaceutica Sinica B 13, no. 1 (2023): 142–156.

[322] J. Cai, X.-J. Zhang, and H. Li, “Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease,” Trends in Endocrinology and Metabolism 29, no. 10 (2018): 712–722.

[323] Z. Lin, P. Yang, Y. Hu, et al., “RING Finger Protein 13 Protects Against Nonalcoholic Steatohepatitis by Targeting STING-relayed Signaling Pathways,” Nature Communications 14, no. 1 (2023): 6635.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.